Cardiff Oncology Inc [CRDF] stock prices are up 8.08% to $3.21 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CRDF shares have gain 11.85% over the last week, with a monthly amount glided 52.13%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cardiff Oncology Inc [NASDAQ: CRDF] stock has seen the most recent analyst activity on January 05, 2026, when Noble Capital Markets initiated its Outperform rating and assigned the stock a price target of $12. Previously, Ladenburg Thalmann started tracking the stock with Buy rating on July 08, 2025, and set its price target to $19. On June 24, 2025, Jefferies initiated with a Hold rating and assigned a price target of $3.50 on the stock. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $8 on September 06, 2024. William Blair initiated its recommendation with an Outperform. Robert W. Baird started tracking with an Outperform rating for this stock on December 08, 2021, and assigned it a price target of $19.
The stock price of Cardiff Oncology Inc [CRDF] has been fluctuating between $1.90 and $4.99 over the past year. Cardiff Oncology Inc [NASDAQ: CRDF] shares were valued at $3.21 at the most recent close of the market.
Analyzing the CRDF fundamentals
The Cardiff Oncology Inc [NASDAQ:CRDF] reported sales of 0.50M for trailing twelve months, representing a drop of -27.27%. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -140.96%, Pretax Profit Margin comes in at -132.37%, and Net Profit Margin reading is -132.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.79, Equity is -0.77 and Total Capital is -1.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.02 points at the first support level, and at 2.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.35, and for the 2nd resistance point, it is at 3.49.
Ratios To Look Out For
It’s worth pointing out that Cardiff Oncology Inc [NASDAQ:CRDF]’s Current Ratio is 4.20. Also, the Quick Ratio is 4.20, while the Cash Ratio stands at 0.69. Considering the valuation of this stock, the price to sales ratio is 432.45, the price to book ratio is 4.41.
Transactions by insiders
Recent insider trading involved PACE GARY W, Director, that happened on Jul 30 ’25 when 0.28 million shares were purchased. Director, PACE GARY W completed a deal on Jul 30 ’25 to buy 15000.0 shares.
